Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Effekten av kartläggning av Sentinel Lymfkörtel på patienten rapporterad nedre extremitetsdysfunktion i stadium I endometriecancer

4 november 2026 uppdaterad av: NRG Oncology

En fas III-studie av effekten av kartläggning av Sentinel-lymfkörtel på patienten rapporterad dysfunktion i nedre extremiteter vid endometriecancer

This phase III trial compares the effect of sentinel lymph node mapping to standard lymph node dissection in reducing the risk of swelling in the legs (lymphedema) in patients undergoing a hysterectomy for stage I endometrial cancer. Standard lymph node dissection removes lymph nodes around the uterus during a hysterectomy to look for spread of cancer from the uterus to nearby lymph nodes. Sentinel lymph node mapping uses a special dye and camera to look for cancer that may have spread to nearby lymph nodes. Comparing the results of the procedures may help doctors predict the risk of long-term swelling in the legs.

Studieöversikt

Detaljerad beskrivning

PRIMARY OBJECTIVES:

I. To compare the rates of lower extremity limb dysfunction (defined as a >= 4-point increase in Gynecologic Cancer Lymphedema Questionnaire [GCLQ] symptom score from baseline) in patients with apparent uterine confined endometrial cancer randomized to one of two lymphatic assessment strategies at time of hysterectomy:

Ia. Sentinel lymph node mapping and excision followed by side-specific lymphadenectomy on sides without a sentinel lymph node (SLN) identified according to a National Comprehensive Cancer Network (NCCN) guidelines approved algorithm (Arm 1); Ib. Sentinel lymph node mapping and excision according to an NCCN Guidelines approved algorithm followed by bilateral pelvic +/- para-aortic lymphadenectomy (Arm 2).

SECONDARY OBJECTIVE:

I. To compare changes in lower extremity limb circumference in patients with apparent uterine confined endometrial cancer randomized to one of two lymphatic assessment strategies at time of hysterectomy.

II. To validate the test characteristics of a SLN mapping algorithm including SLN detection rates, rate of perioperative complications, rate of identifying lymphatic metastases, and detection of micrometastases using pathologic ultra-staging.

EXPLORATORY OBJECTIVES:

I. To compare adjuvant therapy decisions in patients with apparent uterine confined endometrial cancer randomized to one of two lymphatic assessment strategies at time of hysterectomy.

II. To explore the impact of patient characteristics (age, body mass index [BMI], race), extent of lymph node dissection, and adjuvant therapy decisions (radiation, chemotherapy) on the development of lower extremity limb dysfunction - as well as their interaction with lymph node assessment strategies.

III. To evaluate the cost-effectiveness of SLN mapping with or without completion of lymphadenectomy for endometrial cancer.

SAFETY OBJECTIVE:

I. To compare progression free and overall survival in patients with apparent uterine confined endometrial cancer randomized to one of two lymphatic assessment strategies at time of hysterectomy.

OUTLINE: Patients are randomized to 1 of 2 arms.

ARM 1: Patients receive ICG dye via injection and undergo sentinel lymph node mapping and excision during standard minimally invasive hysterectomy. Lymph nodes around the uterus may be removed if the mapping and excision cannot be completed. Successful mapping requires no additional removal of lymph nodes.

ARM 2: Patients receive ICG dye via injection and undergo sentinel lymph node mapping and excision during standard minimally invasive hysterectomy. Additional lymph nodes around the uterus are removed per standard of care.

Patients in both arms also undergo imaging as clinically indicated and optional blood sample collection throughout the study.

After completion of study intervention, patients are followed every 3 months for one year and at 18 and 24 months.

Studietyp

Interventionell

Inskrivning (Beräknad)

428

Fas

  • Fas 3

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

    • District of Columbia
      • Washington D.C., District of Columbia, Förenta staterna, 20037
        • Upphängd
        • George Washington University Medical Center
    • Florida
      • Coral Gables, Florida, Förenta staterna, 33146
        • Rekrytering
        • UM Sylvester Comprehensive Cancer Center at Coral Gables
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 305-243-2647
        • Huvudutredare:
          • Abdulrahman Sinno
      • Deerfield Beach, Florida, Förenta staterna, 33442
        • Rekrytering
        • UM Sylvester Comprehensive Cancer Center at Deerfield Beach
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 305-243-2647
        • Huvudutredare:
          • Abdulrahman Sinno
      • Doral, Florida, Förenta staterna, 33166
        • Rekrytering
        • UM Sylvester Comprehensive Cancer Center at Doral
        • Huvudutredare:
          • Abdulrahman Sinno
        • Kontakt:
      • Miami, Florida, Förenta staterna, 33136
        • Rekrytering
        • University of Miami Miller School of Medicine-Sylvester Cancer Center
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 305-243-2647
        • Huvudutredare:
          • Abdulrahman Sinno
      • Miami, Florida, Förenta staterna, 33176
        • Rekrytering
        • UM Sylvester Comprehensive Cancer Center at Kendall
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 305-243-2647
        • Huvudutredare:
          • Abdulrahman Sinno
      • North Miami, Florida, Förenta staterna, 33181
        • Rekrytering
        • University of Miami Sylvester Comprehensive Cancer Center at Sole Mia
        • Huvudutredare:
          • Abdulrahman Sinno
        • Kontakt:
      • Plantation, Florida, Förenta staterna, 33324
        • Rekrytering
        • UM Sylvester Comprehensive Cancer Center at Plantation
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 305-243-2647
        • Huvudutredare:
          • Abdulrahman Sinno
    • Georgia
      • Augusta, Georgia, Förenta staterna, 30912
        • Rekrytering
        • Augusta University Medical Center
        • Kontakt:
        • Huvudutredare:
          • Robert V. Higgins
    • Illinois
      • Chicago, Illinois, Förenta staterna, 60611
        • Rekrytering
        • Northwestern University
        • Kontakt:
        • Huvudutredare:
          • Emily Hinchcliff
      • Warrenville, Illinois, Förenta staterna, 60555
        • Rekrytering
        • Northwestern Medicine Cancer Center Warrenville
        • Kontakt:
        • Huvudutredare:
          • Emily Hinchcliff
    • Indiana
      • Carmel, Indiana, Förenta staterna, 46032
        • Rekrytering
        • IU Health North Hospital
        • Kontakt:
        • Huvudutredare:
          • Jessica E. Parker
      • Indianapolis, Indiana, Förenta staterna, 46202
        • Rekrytering
        • Indiana University/Melvin and Bren Simon Cancer Center
        • Kontakt:
        • Huvudutredare:
          • Jessica E. Parker
    • Louisiana
      • Marrero, Louisiana, Förenta staterna, 70072
        • Rekrytering
        • West Jefferson Medical Center
        • Kontakt:
        • Huvudutredare:
          • Tara Castellano
      • Metairie, Louisiana, Förenta staterna, 70006
        • Rekrytering
        • East Jefferson General Hospital
        • Kontakt:
        • Huvudutredare:
          • Tara Castellano
      • Metairie, Louisiana, Förenta staterna, 70006
        • Rekrytering
        • LSU Healthcare Network / Metairie Multi-Specialty Clinic
        • Kontakt:
        • Huvudutredare:
          • Tara Castellano
      • New Orleans, Louisiana, Förenta staterna, 70112
        • Rekrytering
        • University Medical Center New Orleans
        • Kontakt:
        • Huvudutredare:
          • Tara Castellano
      • New Orleans, Louisiana, Förenta staterna, 70112
        • Rekrytering
        • Louisiana State University Health Science Center
        • Kontakt:
        • Huvudutredare:
          • Tara Castellano
    • Maryland
      • Baltimore, Maryland, Förenta staterna, 21201
        • Rekrytering
        • University of Maryland/Greenebaum Cancer Center
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 800-888-8823
        • Huvudutredare:
          • Gautam G. Rao
      • Bel Air, Maryland, Förenta staterna, 21014
        • Rekrytering
        • UM Upper Chesapeake Medical Center
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 443-643-3010
        • Huvudutredare:
          • Gautam G. Rao
    • Michigan
      • Detroit, Michigan, Förenta staterna, 48201
        • Rekrytering
        • Wayne State University/Karmanos Cancer Institute
        • Huvudutredare:
          • Robert T. Morris
        • Kontakt:
      • Farmington Hills, Michigan, Förenta staterna, 48334
        • Rekrytering
        • Weisberg Cancer Treatment Center
        • Huvudutredare:
          • Robert T. Morris
        • Kontakt:
      • Flint, Michigan, Förenta staterna, 48532
        • Rekrytering
        • McLaren Cancer Institute-Flint
        • Huvudutredare:
          • Robert T. Morris
        • Kontakt:
    • Minnesota
      • Edina, Minnesota, Förenta staterna, 55435
        • Rekrytering
        • Fairview Southdale Hospital
        • Kontakt:
        • Huvudutredare:
          • Britt K. Erickson
      • Maple Grove, Minnesota, Förenta staterna, 55369
        • Rekrytering
        • Fairview Clinics and Surgery Center Maple Grove
        • Kontakt:
        • Huvudutredare:
          • Britt K. Erickson
      • Maplewood, Minnesota, Förenta staterna, 55109
        • Rekrytering
        • Saint John's Hospital - Healtheast
        • Kontakt:
        • Huvudutredare:
          • Britt K. Erickson
      • Princeton, Minnesota, Förenta staterna, 55371
        • Rekrytering
        • Fairview Northland Medical Center
        • Kontakt:
        • Huvudutredare:
          • Britt K. Erickson
      • Saint Paul, Minnesota, Förenta staterna, 55101
        • Rekrytering
        • Regions Hospital
        • Kontakt:
        • Huvudutredare:
          • Britt K. Erickson
      • Wyoming, Minnesota, Förenta staterna, 55092
        • Rekrytering
        • Fairview Lakes Medical Center
        • Kontakt:
        • Huvudutredare:
          • Britt K. Erickson
    • Missouri
      • Springfield, Missouri, Förenta staterna, 65804
        • Rekrytering
        • Mercy Hospital Springfield
        • Huvudutredare:
          • Jay W. Carlson
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 417-269-4520
    • Montana
      • Billings, Montana, Förenta staterna, 59101
        • Aktiv, inte rekryterande
        • Saint Vincent Healthcare
      • Billings, Montana, Förenta staterna, 59102
        • Aktiv, inte rekryterande
        • Saint Vincent Frontier Cancer Center
      • Billings, Montana, Förenta staterna, 59106
        • Aktiv, inte rekryterande
        • Intermountain Health West End Clinic
      • Butte, Montana, Förenta staterna, 59701
        • Aktiv, inte rekryterande
        • Saint James Community Hospital and Cancer Treatment Center
    • Nebraska
      • Kearney, Nebraska, Förenta staterna, 68845
        • Rekrytering
        • Fred and Pamela Buffett Cancer Center - Kearney
        • Kontakt:
        • Huvudutredare:
          • Kerry J. Rodabaugh
      • Omaha, Nebraska, Förenta staterna, 68198
        • Rekrytering
        • University of Nebraska Medical Center
        • Kontakt:
        • Huvudutredare:
          • Kerry J. Rodabaugh
      • Omaha, Nebraska, Förenta staterna, 68118
        • Rekrytering
        • Nebraska Medicine-Village Pointe
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 402-559-5600
        • Huvudutredare:
          • Kerry J. Rodabaugh
      • Omaha, Nebraska, Förenta staterna, 68124
        • Aktiv, inte rekryterande
        • Alegent Health Bergan Mercy Medical Center
    • Nevada
      • Las Vegas, Nevada, Förenta staterna, 89106
        • Rekrytering
        • Women's Cancer Center of Nevada
        • Huvudutredare:
          • Nicola M. Spirtos
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 702-851-4672
    • Oklahoma
      • Oklahoma City, Oklahoma, Förenta staterna, 73104
        • Rekrytering
        • University of Oklahoma Health Sciences Center
        • Kontakt:
        • Huvudutredare:
          • Christina Washington
    • Pennsylvania
      • Bryn Mawr, Pennsylvania, Förenta staterna, 19010
        • Upphängd
        • Bryn Mawr Hospital
      • Paoli, Pennsylvania, Förenta staterna, 19301
        • Upphängd
        • Paoli Memorial Hospital
      • Wynnewood, Pennsylvania, Förenta staterna, 19096
        • Upphängd
        • Lankenau Medical Center
    • Rhode Island
      • Providence, Rhode Island, Förenta staterna, 02905
        • Rekrytering
        • Women and Infants Hospital
        • Huvudutredare:
          • Matthew T. Oliver
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 401-274-1122
    • Texas
      • Dallas, Texas, Förenta staterna, 75390
        • Rekrytering
        • UT Southwestern/Simmons Cancer Center-Dallas
        • Huvudutredare:
          • Jayanthi S. Lea
        • Kontakt:
      • Dallas, Texas, Förenta staterna, 75235
      • Fort Worth, Texas, Förenta staterna, 76104
        • Rekrytering
        • UT Southwestern/Simmons Cancer Center-Fort Worth
        • Huvudutredare:
          • Jayanthi S. Lea
        • Kontakt:
      • Houston, Texas, Förenta staterna, 77030
        • Rekrytering
        • Memorial Hermann Texas Medical Center
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 713-792-3245
        • Huvudutredare:
          • Joseph A. Lucci
      • Houston, Texas, Förenta staterna, 77030
        • Aktiv, inte rekryterande
        • Houston Methodist Hospital
      • Houston, Texas, Förenta staterna, 77070
        • Aktiv, inte rekryterande
        • Methodist Willowbrook Hospital
      • Houston, Texas, Förenta staterna, 77094
        • Aktiv, inte rekryterande
        • Houston Methodist West Hospital
      • Richardson, Texas, Förenta staterna, 75080
        • Rekrytering
        • UT Southwestern Clinical Center at Richardson/Plano
        • Huvudutredare:
          • Jayanthi S. Lea
        • Kontakt:
      • Sugar Land, Texas, Förenta staterna, 77479
        • Aktiv, inte rekryterande
        • Houston Methodist Sugar Land Hospital
      • The Woodlands, Texas, Förenta staterna, 77385
        • Aktiv, inte rekryterande
        • Houston Methodist The Woodlands Hospital
    • Virginia
      • Charlottesville, Virginia, Förenta staterna, 22908
      • Incheon, Sydkorea, 405-760
        • Rekrytering
        • Gachon University Gil Hospital
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 82-32-460-3213
        • Huvudutredare:
          • Kwang-Beom Lee
      • Seoul, Sydkorea, 05505
        • Rekrytering
        • Asan Medical Center
        • Kontakt:
        • Huvudutredare:
          • Dae-Yeon Kim
      • Seoul, Sydkorea, 06273
        • Rekrytering
        • Gangnam Severance Hospital
        • Huvudutredare:
          • Jae-Hoon Kim
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 82-2-2019-3600
      • Seoul, Sydkorea, 07985
        • Rekrytering
        • Ewha Woman's University Mokdong Hospital
        • Kontakt:
          • Site Public Contact
          • Telefonnummer: 82 2-2650-5114
        • Huvudutredare:
          • Yun H. Kim
    • Gyeongsangnam-do
      • Seoul, Gyeongsangnam-do, Sydkorea, 51353
        • Upphängd
        • Samsung Changwon Hospital

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Kvinna

Beskrivning

Inclusion Criteria:

  • Histologically proven diagnosis of endometrial cancer based on endometrial sampling with a plan to undergo laparoscopic or robotic hysterectomy and lymphatic assessment as part of primary management. Biopsy must be performed within 90 days prior to registration

  • Clinical stage I endometrial cancer based on the following diagnostic workup:

    • History/physical examination within 30 days prior to registration is reassuring for the absence of metastatic disease
  • Age >= 18 years

  • Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1 or 2

  • Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial

  • The patient or a legally authorized representative must provide study-specific informed consent prior to study entry and, for patients treated in the United States (U.S.), authorization permitting release of personal health information

  • Patients must speak English, Spanish, or Korean

Exclusion Criteria:

  • Patients whom the surgeon believes is not a candidate for pelvic lymphadenectomy due to medical comorbidities or other technical challenges (i.e. morbid obesity or prior surgery)

  • History of chemotherapy or immunotherapy for the treatment of endometrial cancer. Progestin-containing therapies such as megestrol, medroxyprogesterone, or levonorgestrel-containing intrauterine device (IUD) are acceptable

  • History of radiation to the pelvis, groin or lower extremities, or surgery to the pelvic lymph nodes or inguinal lymph nodes

  • Patients who are going to undergo another elective surgery during the same operative event as their hysterectomy (i.e., sacrocolpopexy, cholecystectomy)

  • Patients with severe, active co-morbidity defined as follows:

    • History of patient or provider identified lower extremity lymphedema
    • History of patient or provider identified chronic lower extremity swelling
    • History of lower extremity or pelvic deep venous thromboembolism within 90 days of registration
    • History of lower extremity cellulitis within 90 days of registration

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Stödjande vård
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Arm 1 (sentinel lymph node mapping)

Patients receive ICG dye via injection and undergo sentinel lymph node mapping and excision during standard minimally invasive hysterectomy. Lymph nodes around the uterus may be removed if the mapping and excision cannot be completed. Successful mapping requires no additional removal of lymph nodes. Patients also undergo imaging as clinically indicated and optional blood sample collection throughout the study.

Undergo blood sample collection

Andra namn:
  • Biologisk provsamling
  • Bioprov insamlat
  • Provsamling
  • Provuppsamling

Ancillary studies

Undergo imaging

Andra namn:
  • Medicinsk bildbehandling
  • Diagnostisk avbildning

Undergo sentinel lymph node excision

Andra namn:
  • kirurgisk biopsi
  • Biopsi, Excision
  • Excision Biopsy

Given via injection

Andra namn:
  • IC-GRÖN
  • ICG-lösning

Undergo minimally invasive hysterectomy

Andra namn:
  • Minimalt invasiv kirurgi
  • Kirurgi, minimalt invasiv

Undergo pelvic lymphadenectomy

Andra namn:
  • Excision bäcken lymfkörtlar
  • Bäckenlymfkörteldissektion

Undergo sentinel lymph node mapping

Andra namn:
  • Sentinel lymfkörtelavbildning
Experimentell: Arm 2 (sentinel lymph node mapping, pelvic lymphadenectomy)

Patients receive ICG dye via injection and undergo sentinel lymph node mapping and excision during standard minimally invasive hysterectomy. Additional lymph nodes around the uterus are removed per standard of care. Patients also undergo imaging as clinically indicated and optional blood sample collection throughout the study.

Undergo blood sample collection

Andra namn:
  • Biologisk provsamling
  • Bioprov insamlat
  • Provsamling
  • Provuppsamling

Ancillary studies

Undergo imaging

Andra namn:
  • Medicinsk bildbehandling
  • Diagnostisk avbildning

Undergo sentinel lymph node excision

Andra namn:
  • kirurgisk biopsi
  • Biopsi, Excision
  • Excision Biopsy

Given via injection

Andra namn:
  • IC-GRÖN
  • ICG-lösning

Undergo minimally invasive hysterectomy

Andra namn:
  • Minimalt invasiv kirurgi
  • Kirurgi, minimalt invasiv

Undergo pelvic lymphadenectomy

Andra namn:
  • Excision bäcken lymfkörtlar
  • Bäckenlymfkörteldissektion

Undergo sentinel lymph node mapping

Andra namn:
  • Sentinel lymfkörtelavbildning

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Incidence of patient-reported lower extremity limb dysfunction
Tidsram: From 18 months post-hysterectomy after undergoing lymphatic assessment to 39 months

The primary endpoint is the incidence of patient-reported lower extremity limb dysfunction at 18 months post-hysterectomy after undergoing lymphatic assessment according to a National Comprehensive Cancer Network guideline-based sentinel lymph node (SLN) mapping algorithm with or without completion of lymphadenectomy. The primary endpoint will be assessed using the Gynecologic Cancer Lymphedema Questionnaire (GCLQ) questionnaire. Surveys will be performed at enrollment (pre-surgery) and at 3, 6, 9, 12, and 18 months post-surgery. Patient-reported lower extremity limb dysfunction will be defined as an increase in GCLQ symptom score of at least four (4) points from baseline at any time during the 18 months follow-up. The primary null hypothesis will be evaluated with an intent-to-treat chi-squared test, adjusted for stratification factors. Proportional hazards modeling will be used to generate a hazard ratio and 95% confidence limits of Arm 1 versus Arm 2.

From 18 months post-hysterectomy after undergoing lymphatic assessment to 39 months

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
The incidence of lymphedema by quantifiable lower extremity limb changes
Tidsram: From enrollment and at 3, 6, 9, 12, and 18 months after surgery

Patients will undergo circumferential lower extremity limb measures at three locations along each leg. Change will be estimated as measurement at baseline subtracted from measurement at follow-up. This will be assessed in both legs separately.

From enrollment and at 3, 6, 9, 12, and 18 months after surgery
Rate of successful bilateral SLN identification
Tidsram: At time of surgery

Will be assessed in both, and only as the time of surgery.

At time of surgery
Rate of successful identification of lymph node metastasis
Tidsram: At time of surgery

Will be assessed in both, and only as the time of surgery. The rate of lymph node metastasis identification during surgery will be compared between groups, with either t-tests or chi-squared tests where appropriate.

At time of surgery
Rate of perioperative complications
Tidsram: At time of surgery

Will be assessed in both arms separately, and only as the time of surgery. The rate of perioperative complications during surgery will be compared between groups, with either t-tests or chi-squared tests where appropriate.

At time of surgery

Andra resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Adjuvant therapy decisions
Tidsram: Up to 24 months

Adjuvant therapy decisions will be compared for patients according to study arm allocation after accounting for tumor characteristics, stage, and patient demographics to determine whether lymph node mapping strategies was associated with a difference in adjuvant therapy choice.

Up to 24 months
Patient characteristic, extent of lymph node dissection, and adjuvant therapy decisions
Tidsram: Up to 24 months

Patient characteristics (age, body mass index, race), extent of lymph node dissection, and adjuvant therapy decisions (radiation, chemotherapy), will be collected to determine their impact as a covariate on the development of the primary endpoint (lower extremity limb dysfunction). Models adjusting for potential confounders will be fitted and analyzed.

Up to 24 months
Progression free survival
Tidsram: The duration of time from study entry to time of progression or death, whichever occurs first, or date of last contact if neither progression nor death has occurred, assessed at 2 years after enrollment

This endpoint is not expected to be sufficiently powered for a definitive comparison and will therefore be treated as supportive evidence.

The duration of time from study entry to time of progression or death, whichever occurs first, or date of last contact if neither progression nor death has occurred, assessed at 2 years after enrollment
Overall survival
Tidsram: Duration of time from study entry to time of death or the date of last contact, assessed at 2 years after enrollment

This endpoint is not expected to be sufficiently powered for a definitive comparison and will therefore be treated as supportive evidence.

Duration of time from study entry to time of death or the date of last contact, assessed at 2 years after enrollment

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Sponsor

Utredare

  • Huvudutredare: Edward J Tanner, NRG Oncology

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

7 december 2022

Primärt slutförande (Beräknad)

31 mars 2029

Avslutad studie (Beräknad)

31 mars 2030

Studieregistreringsdatum

Först inskickad

2 december 2022

Först inskickad som uppfyllde QC-kriterierna

2 december 2022

Första postat (Faktisk)

12 december 2022

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

6 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

4 november 2026

Senast verifierad

1 november 2026

Mer information

Termer relaterade till denna studie

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera